Algert Global’s Zevra Therapeutics ZVRA Stock Holding History

Algert Global’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-418,550	Closed	-$3.98M	–	1349
2025 Q3	$3.98M	Buy	+418,550	New	+$4.2M	0.07%	475

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Algert Global's ZVRA Position: Q4 2025 in Review

Algert Global sold out of Zevra Therapeutics (ZVRA) in Q4 2025, closing a stake of 418,550 shares — an estimated $3.98M sold.

Algert Global first reported a position in ZVRA in Q3 2025 and held it in 1 quarter. The position peaked at $3.98M in Q3 2025. 158 funds tracked by Wall St. Rank hold ZVRA as of Q4 2025.

Algert Global reported no remaining Zevra Therapeutics position as of Q4 2025 after selling out during the quarter.
Algert Global sold 418,550 Zevra Therapeutics shares in Q4 2025, an estimated $3.98M.
Algert Global first reported a position in Zevra Therapeutics in Q3 2025 and held it in 1 quarter.
Algert Global's Zevra Therapeutics position peaked at $3.98M in Q3 2025.
158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2025.

Based on Algert Global's 13F filing for Q4 2025, filed 17 Feb 2026.